Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Biotech companies such as Biogen (BIIB), Cidara Therapeutics (CDTX), and Theratechnologies (THTX) with the interest of institutional investors could be worth investing in now. Continue reading….

StockNews.com

Merck Stock Today: Why A Bear Call Spread Places $111 In Your Pocket Today

Selling a call spread out of the money in a sideways-to-downside formation has high probabilities of expiring worthless.

Investors Business Daily

Let's Talk About Walgreens Boots Alliance (WBA): Buy, Sell, or Hold?

Walgreens Boots Alliance (WBA) is attempting to raise capital and regain market share. Given this scenario, should investors buy, sell, or hold the stock? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks With Strong Value in August

The biotech industry is ascending with growing R&D initiatives, an upsurge in personalized medicine, and enhanced drug formulations, coupled with the incorporation of technological advancements. So, it seems wise to invest in discounted biotech stocks Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Alkermes (ALKS) this month. Keep reading….

StockNews.com

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

StockNews.com

Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030

Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.

Investors Business Daily

2 Must-Have Pharma Stocks to Buy in August, 1 to Sell

The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals (TEVA) are set to reap the rewards. However, which of the two is the better value stock for August? Read more to find…

StockNews.com

Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.

The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock.

Investors Business Daily

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

StockNews.com

CVS Health Earnings Top Forecasts On Pharmacy Benefits Strength

CVS's pharmacy benefits division hauled in nearly $27 billion in second quarter revenues, offsetting concerns for a surge in medical cost payouts.

The Street

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

StockNews.com

Dangerous diseases found in illegal California medical lab with nearly 1,000 bioengineered mice

Police are still investigating the lab’s origins

The Independent UK

Biotech company settles lawsuit for profiting off of woman’s cloned cells for seven decades

Henrietta Lacks’ unique ‘Hela’ cells played a crucial role in the development of Covid-19 vaccines and treatments for HIV, leukemia and cancer

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Pfizer Covid Sales Extend Slump, Clouding Q2 Earnings Beat

Slowing Covid treatment sales clipped Pfizer's second quarter revenues, clouding its better-than-expected bottom line beat.

Investors Business Daily

Merck Outplays The Covid Decline, But Prometheus Buyout Weighs On Profits

Merck topped second-quarter expectations Tuesday, though it reported a per-share loss. Merck stock toed the line in response.

The Independent UK

Brain fog and other long COVID symptoms are the focus of new small treatment studies

The National Institutes of Health is starting some studies to test possible treatments for long COVID

Zenger

Centene Corporation’s Profits Heavily In Healthcare On Their Second Quarter Profits

The company reported a quarterly revenue of $33.71 billion and a net profit of $1.06 billion in their latest earnings release

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

What's a fair price for a prescription drug? Medicare's about to weigh in

Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

StockNews.com

Top 3 Pharma Stocks You Can’t Miss out On

The ever-transforming pharmaceuticals sector is ready to seize the opportunity to address the growing demand for healthcare across the globe. Therefore, adding these three quality pharma stocks, Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Dr. Reddy's Laboratories (RDY), to your portfolio could prove to be beneficial. Read…

Investors Business Daily

Edwards Lifesciences Sinks Despite An Earnings Beat, Outlook Increase

Edwards Lifesciences stock fell late Wednesday after the medtech company reported Q2 earnings, narrowly topping profit and revenue expectations.

Investors Business Daily

Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

Argenx is up around 40% in 2023. On Thursday, the company reported second-quarter revenue ballooning 230% as sales of its lone product ramp up.

Investors Business Daily

Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines

Pharmaceutical giant GSK beat expectations for the second quarter and raised its forecast for the full year.

The Independent UK

Court says OxyContin maker's bankruptcy and protections for Sackler family members can move ahead

OxyContin maker Purdue Pharma can start its transformation under a bankruptcy agreement that allows the members of the wealthy Sackler family who own the company to avoid civil lawsuits over the opioid crisis, a court has ruled

StockNews.com

Is AbbVie (ABBV) a Better Stock to Buy Than Pfizer (PFE)?

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

1 … 31 32 33 34

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.